About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Austin | 15,205 Studies Near You | Clareo Health

Clinical Trials LocationsAustin

Clinical Trials in Austin

Discover 15,205 clinical trials near Austin, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11281-11300 of 15,205 trials

COMPLETEDPhase 4< 1 mile

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213

This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.

Attention Deficit Hyperactivity Disorder

Noven Therapeutics309 participantsStarted Jan 2007

Scottsdale, Arizona, United States • Irvine, California, United States • San Marcos, California, United States +26 more locations

COMPLETEDPhase 3< 1 mile

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863

To assess the efficacy and safety of efficacy of MTS compared to placebo

Noven Therapeutics217 participantsStarted Jul 2007

Scottsdale, Arizona, United States • Lafayette, California, United States • Wildomar, California, United States +29 more locations

Find Trials by Condition in Austin

Breast Cancerin Austin Lung Cancerin Austin Prostate Cancerin Austin Colorectal Cancerin Austin Melanomain Austin Leukemiain Austin Lymphomain Austin Pancreatic Cancerin Austin Ovarian Cancerin Austin Brain Cancerin Austin Diabetesin Austin

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429

Efficacy and Safety study of Lurasidone in pediatric patients.

Sumitomo Pharma America, Inc.327 participantsStarted Aug 2013

Dothan, Alabama, United States • Anaheim, California, United States • Bakersfield, California, United States +87 more locations

TERMINATEDPhase 462 miles

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970

This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease. The second question will compare the effects of long-term supplementation of vitamin D on death and cancer

Diabetes Mellitus, Type 2

GlaxoSmithKline1,332 participantsStarted May 2009

Long Beach, California, United States • Los Angeles, California, United States • Northridge, California, United States +328 more locations

COMPLETEDPhase 368 miles

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

NCT01572792

The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Long-term efficacy, pharmacoeconomic and health-related quality of life assessments will also be evaluated. This extension study will include a 28 week treatment period, followed by a four week follow up visit. All patients will remain in the same treatment group as for the lead-in study and continue on one of the four treatment arms or placebo.

Chronic Obstructive Pulmonary Disease

AstraZeneca921 participantsStarted Apr 2012

Anniston, Alabama, United States • Athens, Alabama, United States • Birmingham, Alabama, United States +205 more locations

COMPLETEDPhase 374 miles

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459

The purpose of this study is to evaluate the safety, tolerability and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week rin-in period, a 52-week treatment period and a 2-week follow up phone call. All patients will be randomized to one of two doses of aclidinium bromide.

Chronic Obstructive Pulmonary Disease

AstraZeneca605 participantsStarted Nov 2009

Birmingham, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +110 more locations

COMPLETEDPhase 274 miles

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783

The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo (a look-alike tablet without active ingredient). The drugs - nifedipine GITS and candesartan - which are being investigated are currently approved for use in patients with essential hypertension alone or together with other antihypertensive drugs (combination therapy), but the optimal dose of nifedipine GITS and candesartan used together in the treatment of essential hypertension has not been established yet. In this study patients will be treated with various doses of nifedipine GITS and/or candesartan or placebo. These different regimens will be administered once a day and will be assessed based on their blood pressure lowering effects (mean sitting diastolic blood pressure) in subjects with mild to moderate essential hypertension.

Hypertension, Essential

Bayer1,381 participantsStarted Apr 2011

Mobile, Alabama, United States • Los Angeles, California, United States • Coral Gables, Florida, United States +154 more locations

COMPLETED147 miles

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

NCT01571934

Hemophilia A is a genetic deficiency of factor VIII that causes blood to clot too slowly. The disease is classified based on how much factor VIII is in the blood. People with mild or moderate hemophilia A have low, but detectable, blood levels of factor VIII and bleed with trauma or surgery. At the time of surgery, they need to receive factor VIII replacement by infusion into the vein so that blood can clot normally and abnormal bleeding can be avoided. A complication of hemophilia A is the development of an antibody that binds factor VIII and makes the factor VIII infused for treatment not work properly. This antibody is called an inhibitor. In mild and moderate hemophilia A, inhibitors are not common, but have been reported to occur after intensive factor VIII infusions, as may occur at the time of surgery. This study is designed to observe people with mild and moderate hemophilia A who are having surgery. Information on the surgery, treatments given, bleeding, and infection will be gathered. Also, blood will be drawn to determine how the immune system is reacting to the factor VIII. No specific treatments will be given as part of this study. We will use the information to determine what influences inhibitor development. A better understanding of inhibitor development will help medical providers do things to avoid inhibitor development in this population or researchers to design new treatments.

Emory University30 participantsStarted Nov 2011

Aurora, Colorado, United States • Atlanta, Georgia, United States • Indianapolis, Indiana, United States +4 more locations

COMPLETED147 miles

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

NCT01590615

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Gilead Sciences54 participantsStarted Apr 2012

Los Angeles, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +24 more locations

COMPLETEDPhase 2147 miles

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

NCT01830920

The purpose of this study is to determine whether THR-184 when administered around the time of cardiac surgery that requires cardiopulmonary bypass can prevent or ameliorate the development of acute kidney injury.

Acute Kidney Injury

Thrasos Innovation, Inc.452 participantsStarted May 2013

Birmingham, Alabama, United States • Los Angeles, California, United States • Stanford, California, United States +38 more locations

COMPLETEDPhase 3147 miles

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

NCT02290821

This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with acute blunt trauma injuries.

Acute Blunt Soft Tissue Injuries/Contusions

Novartis215 participantsStarted Dec 2014

Bradenton, Florida, United States • Port Orange, Florida, United States • Boise, Idaho, United States +7 more locations

COMPLETEDPhase 2182 miles

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

NCT01482390

This randomized, double-blind, multi-center, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) (MCB) in combination with telaprevir (TVR) and peginterferon Alfa-2a (PEG-IFN) / ribavirin (RBV) in participants with chronic Hepatitis C infection.

Hoffmann-La Roche80 participantsStarted Nov 2011

Birmingham, Alabama, United States • Long Beach, California, United States • Sacramento, California, United States +36 more locations

COMPLETEDPhase 3332 miles

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468

An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.

Purpura, Thrombocytopaenic, Idiopathic

Novartis Pharmaceuticals302 participantsStarted Jun 2006

Huntsville, Alabama, United States • Mobile, Alabama, United States • Jonesboro, Arkansas, United States +107 more locations

COMPLETEDPhase 2391 miles

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

NCT00831779

The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity

Type 2 Diabetes Mellitus

AstraZeneca116 participantsStarted Apr 2009

San Diego, California, United States • Baton Rouge, Louisiana, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3528 miles

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706

Primary objective: \- To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who are inadequately controlled with their current anti-diabetic treatment regimen. Main secondary objective: \- To assess the safety and tolerability of lixisenatide compared to placebo in older T2DM participants (including occurrence of documented (Plasma Glucose PG \< 60 mg/dL) symptomatic hypoglycemia and gastrointestinal side effects). Other secondary objectives: * To assess the effect of lixisenatide compared to placebo after 24-week treatment on: * Fasting plasma glucose (FPG); * During liquid standardized breakfast meal challenge test : 2 hour- Postprandial Plasma Glucose (PPG) and Plasma Glucose Excursion; * 7-point Self-monitored plasma glucose (SMPG) profile; * Body weight; * Change in total daily dose of basal insulin (if taken); * Percentage of participants requiring rescue therapy * Safety and tolerability; * To assess lixisenatide pharmacokinetic profile; * To assess anti-lixisenatide antibody development.

Type 2 Diabetes

Sanofi350 participantsStarted Jun 2013

La Jolla, California, United States • Norwalk, California, United States • Miami, Florida, United States +80 more locations

COMPLETEDPhase 3560 miles

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

NCT01204775

The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.

Type 2 Diabetes

AstraZeneca26 participantsStarted Jun 2011

Los Angeles, California, United States • San Diego, California, United States • Hollywood, Florida, United States +13 more locations

COMPLETEDPhase 2561 miles

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

NCT01160601

This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Non-Squamous Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals86 participantsStarted Jun 2010

Chandler, Arizona, United States • Jonesboro, Arkansas, United States • Whittier, California, United States +37 more locations

COMPLETEDNA578 miles

Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study

NCT00289133

The purpose of this study is to evaluate long-term clinical and radiographic data between geometrically identical GVF and cross-linked polyethylene-bearing inserts in total knee arthroplasty.

Osteoarthritis, KneeArthritis, Rheumatoid

DePuy Orthopaedics938 participantsStarted Feb 2005

Mobile, Alabama, United States • Berkley, California, United States • Fort Collins, Colorado, United States +6 more locations

COMPLETEDPhase 1859 miles

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

NCT01383343

This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with bevacizumab, irinotecan hydrochloride, leucovorin calcium, and fluorouracil in treating patients with colorectal cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Sorafenib tosylate and bevacizumab may also block tumor growth in different ways by targeting certain cells. Giving sorafenib tosylate and bevacizumab together with combination chemotherapy may be a better treatment for colorectal cancer.

Recurrent Colon CarcinomaRecurrent Rectal CarcinomaStage IVA Colon Cancer+3 more

National Cancer Institute (NCI)17 participantsStarted Aug 2011

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 2915 miles

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045

The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the combination to its components, and to assess the relative contribution of the components compared with placebo, in patients with moderate to very severe COPD.

Chronic Obstructive Pulmonary Disease

Pearl Therapeutics, Inc.118 participantsStarted Mar 2010

Clearwater, Florida, United States • Charlotte, North Carolina, United States • Medford, Oregon, United States +13 more locations

PreviousPage 565 of 761Next

Heart Diseasein Austin